Intellia Therapeutics, Inc.

NTLA • Biotechnology

$12.74

▲ +0.06 (+0.47%)

Current price

EarningsLatest report: Jun 30, 2026

HIGHER-RISK PROFILECautionConfidence: 70%

Quantitative profile — not an investment recommendation.

Quantitative profile — not an investment recommendation.Methodology

Analysis thesis: Caution is warranted. Recent ratios show weaknesses that may limit returns unless fundamentals improve.

Market Cap

$1.70B

Growth

—

Cash Flow

0/5

Trend

Negative

Evidence

Positive revenue growth · 7.6%Manageable debt level · 0.14Healthy liquidity · 5.08Weak profitability

Financial data as of: Jun 30, 2026, 12:00 AM UTCLast earnings update: Jun 30, 2026, 12:00 AM UTCLast profile update: Aug 7, 2026, 1:03 PM UTC

Company Snapshot

Key valuation, quality, financial strength, momentum and analyst data.

Price$12.74

Change0.47%

Shares Out133.48M

Market Cap$1.70B

Enterprise Value$1.34B

52W Range7.95 - 28.25

Beta1.77

P/E-4.25

P/S28.58

P/B2.34

P/FCF-3.61

EV/Sales22.45

Price$12.74

Change0.47%

Shares Out133.48M

Market Cap$1.70B

Enterprise Value$1.34B

52W Range7.95 - 28.25

Beta1.77

P/E-4.25

P/S28.58

P/B2.34

P/FCF-3.61

EV/Sales22.45

EV/EBITDA-4.61

EV/FCF-2.84

Earnings Yield-23.52%

FCF Yield-27.68%

Dividend Yield0.00%

Gross Margin76.47%

Oper. Margin-6.52%

Profit Margin-6.10%

Debt/Eq0.14

Current Ratio5.08

Quick Ratio5.08

Target$23.40

Target Upside83.67%

Target Median$20.50

Target Range9.00 - 49.00

Volume4.31M

Avg Volume6.79M

EPS Surprise0.11

Investment DNA

How strong this company looks for long-term investors

out of 100

Business Quality

Margins, moat, returns

22/100

Financial Strength

Debt, cash, stability

76/100

Growth Potential

Revenue and expansion

83/100

Price Attractiveness

Cheap or expensive today

56/100

Why this score▼

Positive revenue growth · 7.6%Manageable debt level · 0.14Healthy liquidity · 5.08Weak profitability

Analyst view

Analyst sentiment and price target

NTLA

Analyst sentiment

Based on 39 analyst votes · 2026-09-05

83/100

Bullish

Hold

Bearish

Price Target

2026-08-07

Low

$9.00

Mean

$23.33

Median

$17.00

High

$49.00

Company Overview

IPO: 5/6/2016

Industry: Biotechnology

P/B i: 2.34

Debt / Equity i: 0.14

Operating Margin: -651.67%

Net Margin: -609.85%

ROE i: -

ROIC: -

Financial Health

Score15 / 20

Debt / Equity: 0.14

Current Ratio: 5.08

Quick Ratio: 5.08

Status: Good

Insider Transactions

Recent executive and insider activity

Dulac Edward J III

Transaction: 07/22/2026

SELL

Change

-8,111

Price

$11.25

Filing

07/24/2026

Type

SELL

Dulac Edward J III

Transaction: 07/02/2026

SELL

Change

-4,677

Price

$18.00

Filing

07/06/2026

Type

SELL

Dube Michael P

Transaction: 07/01/2026

SELL

Change

-2,641

Price

$16.78

Filing

07/06/2026

Type

SELL

Insider	Type	Change	Price	Transaction	Filing
Dulac Edward J III	SELL	-8,111	$11.25	07/22/2026	07/24/2026
Dulac Edward J III	SELL	-4,677	$18.00	07/02/2026	07/06/2026
Dube Michael P	SELL	-2,641	$16.78	07/01/2026	07/06/2026
Bhanji Muna	BUY	+13,300	$12.89	06/09/2026	06/10/2026
Bhanji Muna	BUY	+9,200	Not reported	06/09/2026	06/10/2026
CHASE WILLIAM J	BUY	+13,300	$12.89	06/09/2026	06/10/2026
CHASE WILLIAM J	BUY	+9,200	Not reported	06/09/2026	06/10/2026
Cohen Fred E	BUY	+13,300	$12.89	06/09/2026	06/10/2026
Cohen Fred E	BUY	+9,200	Not reported	06/09/2026	06/10/2026
Goff Brian	BUY	+13,300	$12.89	06/09/2026	06/10/2026
Goff Brian	BUY	+9,200	Not reported	06/09/2026	06/10/2026
GOODMAN JESSE	BUY	+13,300	$12.89	06/09/2026	06/10/2026
GOODMAN JESSE	BUY	+9,200	Not reported	06/09/2026	06/10/2026
Keresty Georgia	BUY	+13,300	$12.89	06/09/2026	06/10/2026
Keresty Georgia	BUY	+9,200	Not reported	06/09/2026	06/10/2026
Verwiel Frank	BUY	+13,300	$12.89	06/09/2026	06/10/2026
Verwiel Frank	BUY	+9,200	Not reported	06/09/2026	06/10/2026
Clark Eliana	SELL	-607	$13.78	03/02/2026	03/03/2026
BASTA JAMES	SELL	-1,211	$13.78	03/02/2026	03/03/2026
Dube Michael P	BUY	+17,250	Not reported	03/01/2026	03/03/2026

About the Company

Intellia Therapeutics, Inc.

Intellia Therapeutics, Inc. is a biotechnology firm dedicated to advancing therapeutic treatments through its expertise in genome editing. The company's pipeline includes several in vivo (administered within the body) programs. NTLA-2001 is currently undergoing a Phase 1 clinical trial for transthyretin amyloidosis, while NTLA-2002 targets hereditary angioedema. Additionally, Intellia is developing various other liver-focused therapies for conditions such as hemophilia A and B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo (processed outside the body) pipeline features NTLA-5001, a candidate for acute myeloid leukemia. The company is also progressing proprietary programs focused on creating engineered cell therapies to address diverse oncological and autoimmune disorders. At the core of Intellia's technology is the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc. has established multiple licensing and collaboration agreements. These include a partnership with Novartis Institutes for BioMedical Research, Inc. to engineer hematopoietic stem cells for treating sickle cell disease, and a co-development agreement with Regeneron Pharmaceuticals, Inc. for potential products against hemophilia A and B. The company also collaborates with Ospedale San Raffaele and holds a strategic alliance with SparingVision SAS to develop novel genomic medicines for ocular diseases, leveraging CRISPR/Cas9 technology. The company, initially known as AZRN, Inc., was founded in 2014 and operates from its headquarters in Cambridge, Massachusetts.

Source - link

Peers

BCRX BHVN IMNM PHVS STOK SYRE UPB WVE ZBIO ZYME

Size reflects market cap · color matches the chart line

1Y peer performance

Top performers + selected company

Latest news

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that on September 1, 2026, it awarded inducement grants to 41 new employees under Intellia's 2024 Inducement Plan, as amended, as a material inducement to employment.

GlobeNewsWire

Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million

$75 million funded upfront with an additional $325 million tied to milestones, providing strategic flexibility through anticipated value inflection points $75 million funded upfront with an additional $325 million tied to milestones, providing strategic flexibility through anticipated value inflection points

GlobeNewsWire

Intellia Therapeutics to Present at Morgan Stanley 24th Annual Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that the company will present at the Morgan Stanley 24th Annual Global Healthcare Conference on Monday, September 14, 2026 at 4:05 p.m. ET.

GlobeNewsWire

Bank of New York Mellon Corp Makes New $6.95 Million Investment in Intellia Therapeutics, Inc. $NTLA

Bank of New York Mellon Corp purchased a new stake in Intellia Therapeutics, Inc. (NASDAQ: NTLA) in the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 410,654 shares of the company's stock, valued at approximately $6,948,000. Bank of New York Mellon Corp owned approximately

Defense World

Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought

Ark Invest was a buyer of tech stocks down as much as 53% from their recent all-time highs.

Fool - Investing News

Earnings Surprises

Period	Estimate	Actual	Surprise
2026-05-11	-0.92	-0.81	0.11
2026-02-26	-0.99	-0.83	0.16
2025-11-06	-1.02	-0.92	0.1
2025-08-07	-1.03	-0.99	0.04
2025-05-08	-1.26	-1.1	0.16
2025-02-27	-1.32	-1.24	0.08
2024-11-07	-1.37	-1.34	0.03
2024-08-08	-1.21	-1.31	-0.1
2024-05-09	-1.35	-1.06	0.29
2024-02-22	-1.47	-1.46	0.01
2023-11-09	-1.52	-1.38	0.14
2023-08-03	-1.32	-1.4	-0.08